Comparative Pharmacology
Head-to-head clinical analysis: DUVOID versus MYOTONACHOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUVOID versus MYOTONACHOL.
DUVOID vs MYOTONACHOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective alpha-1A adrenergic receptor antagonist; relaxes smooth muscle in the bladder neck and prostate, reducing outflow resistance.
Myotonachol (bethanechol chloride) is a direct-acting parasympathomimetic agent that selectively stimulates muscarinic acetylcholine receptors, particularly M3 subtypes, in smooth muscle of the gastrointestinal tract and urinary bladder. It mimics the action of acetylcholine but is resistant to hydrolysis by acetylcholinesterase, leading to increased smooth muscle tone and peristalsis.
100 mg orally three times daily.
25 mg orally three times daily. Maximum dose 100 mg four times daily.
None Documented
None Documented
Terminal elimination half-life is 12–15 hours in patients with normal renal function; prolonged to 24 hours or more in moderate-to-severe renal impairment.
Terminal elimination half-life: 1.5-2.5 hours (prolonged in renal impairment).
Renal elimination accounts for approximately 90% of a dose as unchanged drug; biliary/fecal excretion is minor (<10%).
Renal: 70-80% unchanged; biliary/fecal: 20-30% as metabolites.
Category C
Category C
Cholinergic Agonist
Cholinergic Agonist